Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
暂无分享,去创建一个
Steven J Brown | B. Bibby | M. Kamm | J. Andrews | P. Bampton | R. Gearry | I. Lawrance | G. Radford-Smith | L. A. Christensen | P. Gibson | K. Subramaniam | S. Connor | N. Jensen | C. Hvas | J. Kjeldsen | S. Bell | W. Connell | M. Sparrow | H. Kammerlander | M. Julsgaard | T. Vestergaard | J. Fallingborg | A. Walsh | G. Moore | S. Wildt | Mille Baekdal | T. Boysen | L. Svenningsen | B. Wilson | Kathrine Ellard | L. Christensen | J. Andrews
[1] M. Dubinsky,et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. , 2019, Inflammatory bowel diseases.
[2] W. Czuber-Dochan,et al. Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients′ reproductive health , 2018, Alimentary pharmacology & therapeutics.
[3] A. Barkun,et al. Continuous Anti‐TNF&agr; Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION) , 2018, The American Journal of Gastroenterology.
[4] J. Gisbert,et al. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study , 2018, The American Journal of Gastroenterology.
[5] B. Nørgård,et al. Anti–TNF-&agr; Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight , 2017, Inflammatory bowel diseases.
[6] R. Gearry,et al. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.
[7] Christopher F. Martin,et al. Exposure to Biologic Therapy and Childhood Development among Offspring of Women with Inflammatory Bowel Disease: Results from the Piano Registry , 2017 .
[8] G. Nguyen,et al. "Just in Time": When Is It Safe to Administer Live Vaccines to Infants Exposed to Anti-Tumor Necrosis Factor Agents In Utero? , 2016, Gastroenterology.
[9] C. J. van der Woude,et al. Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] Steven J Brown,et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. , 2016, Gastroenterology.
[11] A. Bitton,et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. , 2016, Gastroenterology.
[12] D. Kennedy,et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. , 2015, British journal of clinical pharmacology.
[13] C. J. van der Woude,et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety , 2015, Gut.
[14] C. J. van der Woude,et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.
[15] J. Andrews,et al. It IS worth the effort: Patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session. , 2014, Journal of Crohn's & colitis.
[16] M. Nørgaard,et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn’s disease , 2014, Scandinavian journal of gastroenterology.
[17] M. Nørgaard,et al. Influence of medical treatment, smoking and disease activity on pregnancy outcomes in Crohn's disease , 2014, Scandinavian journal of gastroenterology.
[18] M. Dubinsky,et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[19] A. Hokken-Koelega,et al. Circulating maternal cytokines influence fetal growth in pregnant women with rheumatoid arthritis , 2012, Annals of the rheumatic diseases.
[20] J. Mclaughlin,et al. Patients' knowledge of pregnancy‐related issues in inflammatory bowel disease and validation of a novel assessment tool (‘CCPKnow’) , 2012, Alimentary pharmacology & therapeutics.
[21] M. Nørgaard,et al. Self‐reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis , 2011, Inflammatory bowel diseases.
[22] M. Nørgaard,et al. Self‐reported antenatal adherence to medical treatment among pregnant women with Crohn’s disease , 2010, Alimentary pharmacology & therapeutics.
[23] A. Kornbluth,et al. Relapses of Inflammatory Bowel Disease During Pregnancy: In-Hospital Management and Birth Outcomes , 2008, The American Journal of Gastroenterology.
[24] R. Devlieger,et al. Maternal obesity: pregnancy complications, gestational weight gain and nutrition , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[25] J. Bartha,et al. Inflammatory cytokines in intrauterine growth retardation , 2003, Acta obstetricia et gynecologica Scandinavica.
[26] D. Barker,et al. Mothers' pelvic size, fetal growth, and death from stroke and coronary heart disease in men in the UK , 1996, The Lancet.
[27] D J Barker,et al. Fetal origins of coronary heart disease , 1995, BMJ.
[28] D. Barker,et al. WEIGHT IN INFANCY AND DEATH FROM ISCHAEMIC HEART DISEASE , 1989, The Lancet.
[29] L. Keefer,et al. Documentation of reproductive health counseling and contraception in women with inflammatory bowel diseases. , 2014, Patient education and counseling.
[30] A. Harris,et al. Carboplatin/cisplatin , 2012, Reactions Weekly.